

R&D

I-STAR™ Antibody Discovery Platform

Targeted Patient Population

Titer-positive individual

- > Convalescent
- > Vaccinated





Clinical Studies

- > Human mAB
- > Not patient-specific

Fresh frozen sample; IgG+ memory B-cell isolation





DAY 0

B Cell Activation

- > 7 day culture of IgG+ memory B cells
- > Expansion & differentiation > Preliminary evaluation to IgG-secreting cells
- > Naturally expressed Abs

DAY 7

Antibody Screening

- > High throughput
- > Binding to target

DAY 21

Antibody Recovery

- > Rescue by RT-PCR
- Recombinant human mAb
- > Monoclonal production

Preclinical Development



+ 2-4 MONTHS

Antibody Evaluation

- > Functional assays
- > Binding affinity
- > Effector function
- > Biophysical characterization